|
|
|
| Clinical Research of Targeted Therapy in 72 Patients with Advanced Lung Adenocarcinoma |
| The First Affiliated Hospital of Nanchang University，Nanchang 330006，China |
|
|
|
|
Abstract Objective：To analyze and study the clinical effect of targeted therapy in the treatment of advanced lung adenocarcinoma and to provide certain theoretical basis for the future direction of cancer therapy.Method：72 cases of lung adenocarcinoma patients in the respiratory medicine of our hospital from May 2010 to May 2014 were selected as the research objects.22 cases were given first-line treatment，50 cases were given second-line treatment.Patients were given Gefitinib orally at a dose of 250 mg per day and they couldn’t take other drugs within 1 hour before and after drug use.This treatment was continued until the tumor progression or the occurrence of intolerable side effects.Patients with bone metastases were given Zoledronic acid and patients with brain metastasis were given r knife radiotherapy.Result：In the patients with first-line treatment，6 cases were complete remission，9 cases were partial response and 7 cases were stability.The median alleviate time was（ 7.6±0.5） months，the median tumor progression time was（ 8.5±0.6） months and the median follow-up was 14 months（4-24 months）.4 patients with first-line treatment died.Among the patients with second-line treatment，8 cases were partial response，26 cases were stability and 16 cases were partial response，the median relief time was（ 6.5±0.4）months，the median tumor progression time was（ 7.2±0.5） months and the median follow-up was 12 months（ 4-30 months）.8 patients with second-line treatment died.The total effective rate of the first-line treatment was higher than that of the second-line treatment，the difference was statistically significant（P<0.05）. The main adverse reactions were rash，pruritic skin and liver function lesion，the extent of degree was mainly 1 to 2 degree.Conclusion：In the targeted therapy of lung adenocarcinoma，Gefitinib with first-line treatment is better than Gefitinib with second line treatment.It has the advantages of high safety and little side effects.But its price is expensive，so it can’t be fully widespread used.
|
|
|
|
|
|
|
|
|
